Replies to post #566 on Intellipharmaceutics International Inc. (IPCI)

[doogdilinger]

Credible sources told BioMedReports on Monday that the company's first FDA approval may finally be set for announcement "very shortly."

[doogdilinger]

Their CEO, Dr. Isa Odidi, is easily considered one of the sector's top drug delivery innovators. When Odidi was at Biovail- which merged with Valeant Pharmaceuticals International (NYSE: VRX)(TSX:VRX) in 2010, he was performing drug alchemy with formulations that mimicked several hard-to-manufacture generic versions of expensive drugs- among them, Pfizer’s (NYSE: PFE ) Procardia XL, Bayer’s OTC: (BAYRY.PK ) Adalat CC, and Novartis’ (NYSE: NVS ) Voltaren XR.

While serving as Biovail’s Vice President of Research of Drug Development and New Technologies he helped grow Biovail into a multi-billion dollar company. Now he’s doing it all over again, this time with his own emerging biotech-- and many see it as extremely undervalued, given the events which are set to transpire there. That sentiment is underscored by the fact that the company is close to FDA approval and plans immediate commercialization of those drug candidates.